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Staphylococcus aHreHS and streptococci secrete a large 
family of exotoxins involved in the pathogenesis of 
toxic-shock-like syndromes and have been impli­
cated in several autoimmune disorders. These toxins 
act as prototypic superantigens capable of binding to 
major histocompatibility complex proteins on anti­
gen-presenting cells outside the antigen peptide­
binding groove and can thereby stimulate cytokine 
release from macrophages. The superantigen-major 
histocompatibility complex unit is recognized pri­
marily by the variable region of the T-cell receptor 
BACKGROUND 
The term "superantigen" was first coined by White et al [1] in 1989 
and refers to a group of microbial antigens that differ in several 
respects from conventional peptide antigens (reviewed in [2,3]). 
Similar to peptide antigens, superantigens are presented by class II 
major histocompatibility complex (MHC) molecules. However, 
they do not engage the MHC peptide-antigen binding groove. 
Instead, the intact (unprocessed) superantigen binds to conserved 
amino acid residues that are on the outer walls of the peptide­
-antigen binding groove. Thus, whereas recognition of peptide 
antigens by the T-cell receptor (TCR) is restricted by MHC alleles, 
recognition of superantigens is generally not MHC restricted. More 
important, the recognition of superantigens by TCRs depends 
predominantly on the variable domain of the TCR beta chain (Vf3). 
Conventional peptide antigens require recognition by all five 
variable elements (i.e., V(3, D(3, J(3, Va, Ja) of the TCR. There­
fore, the responding frequency to a conventional antigen is usually 
much less than one in 1000. In contrast, because the relative 
number of V(3 genes is restricted, the frequency ofT cells respond­
ing to these molecules exceeds that of conventional peptide 
antigens by several orders of magnitude, hence their name "super­
antigens." 
Duting the past 5 years, there has been an explosion of informa­
tion regarding the biochemical and immunologic properties of 
superantigens. Furthermore, an increasing number of bacterial-, 
mycoplasmal-, and viral-derived proteins have been identified as 
superantigens [2,3]. The potential role of superantigens in human 
disease, particularly with regard to the skin , is of considerable 
interest. However, because of the complexities of studying cause­
and-eifect relations in the clinical setting, information on the role of 
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Abbreviations: APC, antigen-presenting cell(s); SE, staphylococcal ente­
rotoxins; SPE, streptococcal exotoxins; TCR, T-cell receptor, V(3, variable 
region of the TCR (3 chain. 
beta chain, and by engaging this region, can activate 
a large portion of the T-cell repertoire. It is thought 
that the capacity of these toxins to cause the massive 
stimulation of T cells and accessory cells such as 
macrophages, Langerhans cells, and activated kera­
tinocytes accounts for most of their pathologic ef­
fects. The current review examines the evidence that 
implicates a role for these superantigens in the patho­
genesis of certain skin diseases. J Invest Dennatol 
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superantigens in mediating human disease remains limited. The 
current review examines the immunologic eifects of superantigens, 
particularly as they may relate to the skin. 
IMMUNOBIOLOGY OF SUPERANTIGENS IN THE SKIN 
The unique capacity of superantigens to bind directly to MHC class 
II molecules on the one hand, and to stimulate a large fraction ofT 
cells expressing relevant TCR V f3 chains ou the other hand, 
provides a number of immune mechanisms by which these potent 
molecules can participate. As shown in Table I, staphylococcal 
enterotoxins (SE) and streptococcal exotoxins have been demon­
strated to act as prototypic superantigens [4]. These superantigens 
have been demonstrated to act as potent inducers of interleukin 
(1L)-1 and tumor necrosis factor (TNF)-a from monocytes [5]. 
SE-mediated stimulation ofmonocytes is a consequence of binding 
and transducing a positive signal through MHC class II molecules 
on monocytes [6,7]. Although SEs bind to class II molecules in an 
unrestricted manner, human leukocyte antigen (HLA)-DR alleles 
diifer in their ability to present SEs to T cells [8]. 
Recently, several laboratories have examined the ability of 
epidermal Langerhans cells and/or keratinocytes to act as accessory 
cells in the T-cell response to staphylococcal superantigens. Murine 
splenic T cells were stimulated with staphylococcal enterotoxin B 
(SEB) and exfoliative toxin in the presence of Langer hans cells or 
epidermal cells isolated from mice pretreated with recombinant 
interferon (IFN)-y, a procedure that induces the expression of 
MHC class II molecules on keratinocytes [9] . Similarly, cultured 
human keratinocytes that have been induced in vitro to express 
MHC class II molecules on their cell surface by IFN-y acquire the 
ability to activate T cells in the presence of super antigens [10,11]. 
This activation was demonstrated to require direct contact between 
keratinocytes and T cells, because monoclonal antibodies to human 
HLA-DR, HLA-DQ, intercellular adhesion molecule-1 (ICAM-l), 
and lymphocyte function-associated antigen-l (LFA-1) blocked 
SEB-induced T-cell stimulation. Of interest, unlike Langerhans 
cells , keratinocytes bearing MHC class II are unable to present 
conventional peptide antigens to resting T cells . These findings, 
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Table I. Human TCR V{1 Specificities of Bacterial 
Superantigensa 
Bacterial Exotoxin 
SEA 
SEB 
SEC1 
SED 
SEE 
TSST-1 
Exfoliative toxin 
SPEA 
SPEB 
SPEC 
Mycoplasma arthritidis mitogen 
a Reviewed in [3]. 
TCR V{3 
Specificity 
1.1,5,6,7.3-7.4,9.1 
3,12,14,15,17,20 
3,6.4,6.9,12,15 
5,12 
5.1,6,8,12 
2 
2 
8,12,14,15 
2,8 
1,2,5.1,10 
3,17 
however, suggest that under certain pathologic conditions, e.g., 
during S. aureus or streptococcal skin infections, class II (+) 
keratinocytes can serve as accessory cells. 
These recent studies have also demonstrated that murine and 
human keratinocytes can release cytokines with T -cell-activating 
activities after exposure to staphylococcal toxins. In particular, the 
production of TNF-a, but not IL-la, was enhanced by SEB [9]. 
The capacity of keratinocytes to release cytokines in response to 
superantigenic stimulation is of interest because it is well established 
that T-cell differentiation is influenced by the cytokines released 
during antigen-driven stimulation. In this regard, Goodman et al 
[12] compared the profile of cytokines produced by T cells 
stimulated by SEB in the presence of MHC class II (+) keratino­
cytes with the response seen using dermal dendritic cells. T cells 
stimulated in the presence of dermal dendritic cells produced the 
Thl cytokines IL-2 and IFN-'Y, whereas T cells stimulated in the 
presence of activated keratinocytes produced only the Th2 cytokine 
IL-4. This dichotomy in T-cell responses appears to relate to the 
inability of keratinocytes to produce IL-12 after SEB stimulation. 
More important, these observations suggest that the nature of the 
primary T-cell response can be determined by the accessory cell 
used for antigen presentation. 
Studies in experimental animals have demonstrated that superan­
tigens have three principal in vivo effects on T cells bearing the 
relevant V{1 elements [2,3]. First, exposure of developing thymo­
cytes to superantigens causes intrathymic deletion of T cells of 
appropriate V {3 specificity, with resultant skewing of the T-cell 
repertoire. Second, exposure of peripheral T cells to superantigens 
results in profound activation and lymphocytosis of T cells of 
appropriate V{3 specificity, and under certain conditions, this may 
be followed in time by anergy and/or deletion of the stimulated 
T-cell clones. Finally, exposure of peripheral T cells to superanti­
gens can have profound physiologic consequences, related largely 
to massive cytokine release by T cells and antigen-presenting cells 
(APC). The particular response of T cells to superantigens depends 
on a variety of factors, including their developmental and activa­
tional state as well as the accessory signals provided by the 
superantigen-presenting cell. The extent to which these observa­
tions, mainly achieved in experimental animal models, relate to 
actual human diseases remains to be clarified. Nevertheless, the 
marked immunomodulatory effects of superantigens on T cells has 
led to widespread speculation that these molecules may provide the 
basis by which microbes may mediate a variety of diseases associ­
ated with immunodeficiency, autoimmunity, and/or inflammation 
(reviewed in [3]). 
IDENTIFlCA TION OF SUPERANTIGENS IN 
HUMAN DISEASE 
The role of superantigens in immune-mediated human disease is an 
area of intense investigation. Superantigens are thought to play a 
role in the pathogenesis of a number of systemic disease conditions 
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in which the development of skin inflammation is a prominent 
feature. These include staphylococcal toxic shock syndrome (TSS) 
and Kawasaki syndrome (KS). Before considering superantigens in 
primary skin diseases, it is instructive to review the data that have 
been used to support a role for superantigens in staphylococcal TSS 
and KS, as they provide potential criteria that may be useful to 
establish a cause-and-effect relation between superantigens and 
T-cell-mediated diseases. 
Staphylococcal TSS TSS is an acute disease characterized by 
fever, rash, shock, and multiorgan involvement [13]. More than 
90% of S. aureus strains isolated from menstruation-related cases 
produced TSS toxin-l (TSST-l). The absence of specific antibody 
to TSST-l appears to be a major risk factor for acquiring the 
disease. In nonmenstrual cases, TSST-l is implicated in less than 
50% of cases, and SEB and SEC production plays a more important 
role. Chio et al [14] demonstrated that the majority of T cells 
stimulated by TSST -1 in culture specifically expressed V {32. Based 
on these in vitro findings, studies were carried out to determine the 
T-cell repertoire in patients with TSS. The majority of patients with 
TSS were found to have a marked and selective expansion ofV{32+ 
T cells. Serial evaluation of patients during the convalescent phase 
of their illness showed a gradual return of V {32 levels toward 
normal, suggesting that the increase in V{32+ T cells occurs after 
the onset of TSS. 
The mechanisms by which TSST-l produces the manifestations 
of TSS are unknown. Cytokines such as TNF-a have been 
implicated as a cause of shock. This cytokine is released in cultures 
of monocytes after the addition of TSST -1, and elevated levels of 
TNF-a have been documented during acute disease [5]. However, 
studies in animals also support an important role for T cells in 
superantigen-mediated lethal shock. Pretreatment of m:ice with 
D-galactosamine leads to the development of lethal shock when the 
mice are challenged with low doses of either lipopolysaccharide or 
SEB. Shock in both cases can be shown to be mediated by TNF. It 
is interesting that the lethal shock triggered by SEB was shown to 
be mediated by T cells [15]. In contrast, endotoxin (lipopolysac­
charide )-induced shock appeared to be independent of T cells. 
Consistent with a role for T cells in the pathogenesis of shock, 
shock-like syndromes have been reported in cancer patients being 
given large amounts of T-cell-derived IL-2 [16] and in allograft 
recipients being treated with anti-CD3 monoclonal antibodies [17]. 
Taken together, the observations of T-cell-dependent shock in 
animals injected with superantigen, the massive stimulation of 
V{32+ T cells during TSS, and the isolation of TSST-l-, SEB-, or 
SEC-secreting S. aureus from patients with TSS support the concept 
that superantigens play an important role in the pathogenesis of this 
disease. 
Kawasaki Syndrome KS is an acute multisystem vasculitis that 
primarily affects infants and young children (reviewed in [18]). The 
primary clinical features of acute KS include high fever, nonexu­
dative conjunctival injection, inflammation of the oropharynx, 
erythema and edema of the hands and feet, polymorphous rash, and 
cervical lymphadenopathy. Although acute KS is generally self 
limited, coronary artery abnormalities due to vasculitis can develop 
in up to 25% of untreated patients. In Japan and the United States, 
KS has become one of the most common causes of acquired heart 
disease in children. Treatment of acute KS with high doses of 
intravenous gamma globulin significantly decreases the occurrence 
of coronary artery abnormalities. 
The etiology of KS remains unknown. However, it is widely 
believed that KS is caused by an infectious agent because of the 
acute self-limited nature of this disease, its seasonal incidence, the 
geographic clustering of outbreaks, the clinical symptoms of fever 
and exanthem mimicking bacterial toxin-mediated infectious dis­
eases, and the unique susceptibility of infants and young children. 
The observation that children younger than 6 months or older than 
8 years rarely develop acute KS suggests that the lack of a protective 
antibody against the putative KS agent may be an important risk 
factor for development of this disease. 
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A number of studies have demonstrated that the acute, but not 
the convalescent, phase ofKS is associated with marked activation 
ofT cells and monocytes/macrophages (reviewed in [19]). Further­
more, successful treatment ofKS with intravenous gamma globulin 
i$ associated with a significant reduction in immune activation [20]. 
Based on these immunologic features, which are characteristic of 
diseases caused by bacterial toxins acting as superantigens, studies 
were conducted on the ,T lymphocytes of patients with acute KS for 
evidence of selective TCR V{3 gene usage. In a study from our 
laboratory, peripheral blood mononuclear cells from 19 patients 
with acute KS were analyzed for TCR V{3 gene expression. Patients 
with KS demonstrated elevated levels of V{32+, and to a lesser 
extent V{38.1 + T cells compared with cells from normal donors 
and from controls with other febrile illnesses [21,22]. During 
convalescence, the proportions of V{32+ and V{38.1 + T cells 
retumed to normal levels. None of the other TCR V{3 populations 
were found to be elevated. These results are consistent with the 
hypothesis that the immune stimulation of KS is triggered by a 
bacterial toXin with superantigenic activity. 
As noted above, superantigens stimulate T cells primarily 
through the V{3 portion of the TCR and therefore induce an 
expansion ofT cells independent of the TCR {3-chainjunctional or 
CDR3 (diversity) regions. To determine whether V{32+ and V{38+ 
T cells were expanded in a superantigen-like (polyclonal) as 
opposed to an oligo clonal marmer in acute KS, sequences of 
random cDNA clones containing V{32 and V{38 gene segments 
were analyzed [22]. In patients with a two- to threefold increase in 
V{32 gene expression, one might expect that up to 60% of the 
sequences would reflect the abnormally expanded T cells. How­
ever, none of the V{32 sequences were found to be identical to 
another. These data indicate that in the expansion ofV{32+ T cells 
in acute KS, V{3 itself plays the dominant role in recognition. 
Together with the high frequency of responding V{32+ T cells in 
the circulation, which is disproportionate to that expected for a 
response to a conventional antigen, the results appear to be most 
consistent with the hypothesis that T-cell activation during acute 
KS is mediated by a superantigen. 
To address the hypothesis that a bacterial toxin might be the 
cause of the superantigenic immune activation, Leung et al [23] 
carried out the following study. Skin (groin, axilla) and mucous 
membrane (rectum, throat) cultures were obtained from 16 patients 
with acute KS and 15 control patients with fever and/or rash. All 
group A {3-hemolytic streptococci and all �oagulase-positive S. 
aureus isolates were screened for toxin production in a blinded 
fashion. Bacteria-producing superantigens were found in 13 of 16 
KS patients, but in only one of 15 control patients (p < 0.0001). 
Eleven qf 13 toxin-positive cultures from patients with KS were 
due to TSST -elaborating S. aureus, and two of 13 were due to 
streptococci-producing pyogenic exotoxins B and C. Each of these 
toxins is known to possess V{32 stimulatory activity. 
Of interest, the toxin-producing S. aureus from the 11 KS patients 
were unusual because they produced less lipase, hemolysin, and 
protease than conventional S. aureus and because the bacteria were 
white rather than the customary gold appearance. These findings 
suggest that the immune activation associated with the acute phase 
of KS may indeed be caused by a novel strain of S. aureus or to a 
lesser extent by streptococci that colonize mucous membranes and 
elaborate toxins with superantigenic activity. Furthermore, the 
observation that the dUferent bacterial toxins associated with KS are 
potent activators ofV{32+ T cells suggests an important role for this 
T-cell subset in the pathogenesis of this disease. 
The capacity of bacterial exotoxins (superantigens) to bind to 
MHC class II molecnles on monocytes/macrophages or to stimu­
late T cells bearing particular TCR V{3s provides several mecha­
nisms by which a putative superantigen could cause acute KS. First, 
exotoxins secreted at the inflamed mucosal surface could be 
absorbed and engage HLA-DR on local or circulating macrophages 
to stimulate the production ofIL-l{3 and TNF-ri, which both have 
potent proinflammatory properties, and thus contribute to vascular 
inflanunation. Second, as in TSS, T-cell stimulation may be critical 
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for cytokine release, with the subsequent induction of adhesion 
molecules that localize inflammatory cells to the vascular wall, and 
may thus play an important role in the pathogenesis of vasculitis in 
acute KS. Third, superantigens could induce autoreactive T cells 
that recognize vascular antigens and are involved in the more 
persistent manifestations of KS. 
SUPERANTIGENS AND SKIN DISEASES 
Several primary skin disorders are associated with the presence of 
bacteria, in particular S. aureus and streptococci, that produce 
superantigenic toxins. These include staphylococcal scalded-skin 
syndrome, in which exfoliation of the skin occurs. Exfoliation is 
primarily due to the separation of granular-layer keratinocytes, 
possibly by binding of exfoliative toxin to desmoglein I [24]. In 
addition, it is well known that bacterial infection can exacerbate a 
variety of chronic inflammatory skin diseases such as atopic derma­
titis and certain forms of psoriasis. Such associations of skin 
disorders and superantigens have led a number of investigators to 
examine the immunomodulatory consequences of bacterial toxins 
in these patients. 
Atopic Dennatitis Atopic dermatitis is a chronic pruritic in­
flammatory skin disorder characterized by the local infiltration ofT 
cells and monocytes/macrophages (reviewed in [25]). Several 
observations suggest that the expansion of T -helper type 2 (Th2) 
cells and allergen sensitization play a role in the pathogenesis of this 
disease. First, the majority of patients with atopic dermatitis have a 
personal or fumily history of atopic disease, e.g., asthma or allergic 
rhinitis. Second, serum 19E levels are elevated in about 80% of 
patients with atopic dermatitis, and their serum IgE levels often 
correlate with the extent of skin disease. Third, most patients with 
atopic dermatitis produce 19E to various food and inhalant aller­
gens, and double-blind, placebo-controlled food challenge studies 
have demonstrated that food allergies can trigger cutaneous reac­
tions in a subset of children with atopic dermatitis. Fourth, mite­
specific Th2-type lymphocytes have been cloned from the periph­
eral blood and skin lesions of atopic dermatitis patients with 
19B-specific antibody to dust mites [26,27]. More recently, in situ 
hybridization studies have demonstrated that acute atopic derma­
titis skin lesions express increased levels ofIL-4 and IL-5, but not 
IFN-y mRNA [28] . 
Although food- and inhalant-induced eczema has been reported 
in this disease, it has been argued that such reactions may involve 
only a minority of patients with atopic dermatitis. Numerous 
reports have shown that S. aureus can exacerbate this skin disease. 
Leyden et al [29] first demonstrated that S. aureus could be isolated 
from the alfected skin of more than 90% of patients with atopic 
dermatitis. By quantitative methods, the density of S. aureus on 
inflamed atopic dermatitis lesions can reach up to 107 colony­
forming units/cm2 [30]. Clinically, it is also well known that 
patients with chronic atopic dermatitis show a better clinical 
response to combined treatment with antistaphylococcal antibiotics 
and topical corticosteroids than to corticosteroids alone [31]. 
To study potential mechanisms by which S. aureus can exacerbate 
atopic dermatitis, Leung et al [32] characterized S. aureus from the 
skin of patients with atopic dermatitis for their capacity to secrete 
toxins known to have superantigenic properties. More than haif of 
atopic dermatitis patients secreted identifiable toxins, primarily 
SEA, SEB; and TSST-1. The capacity ofSEs to bind to MHC class 
II molecules and to stimulate T cells bearing particular TCR V{3s 
suggests several mechanisms by which S. aureus could exacerbate 
atopic dermatitis. First, SEs secreted at the skin surface could 
penetrate inflamed skin and engage HLA-DR on epidermal mac­
rophages or Langerhans cells to stimulate the production of IL-l 
and TNF-a. IL-l and TNF-a have potent proinflammatory prop­
erties, which contribute to skin inflammation. Second, SEs could 
stimulate a high proportion of T cells via their TCR V{3 to 
proliferate and secrete cytokines, which modulate tissue inflamma­
tion. Indeed, Th2 cells expanded in vitro with superantigens have 
been demonstrated to induce inflammation when injected into the 
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Figure 1. Antigen presentation to T Iytnphocytes. 
skin of naive animals [33]. Furthermore, preliminary studies from 
our laboratory indicate that acute atopic dermatitis lesions can be 
associated with the selective expansion ofT cells expressing specific 
TCR Vf3 gene segments. 
Because SEs are globular proteins of 24-30 kD, the possibility 
that they could act as allergens was also investigated [32]. In this 
regard, it has been found that nearly half of patients with atopic 
dermatitis produce IgE directed to staphylococcal toxins, particu­
larly SEA, SEB, and TSST-1. To study the potential functional role 
ofIgE antistaphylococcal toxins, we investigated the capacity of SEs 
to induce histamine release from freshly isolated basophils of 
normal individuals and patients with AD. Basophils from normal 
controls and atopic dermatitis patients who lacked IgE antitoxin 
failed to release any histamine on exposure to the various staphy­
lococcal exotoxins. In contrast, basophils from atopic dermatitis 
patients who produced IgE antitoxin released histamine on expo­
sure to the relevant exotoxin, but not in response to exotoxins in 
which there is no IgE response [32]. These findings suggest the 
possibility that local production of staphylococcal exotoxins at the 
skin surface could cause IgE-mediated histamine release and 
thereby trigger the itch-scratch cycle that can exacerbate atopic 
dermatitis. 
Psoriasis Immune activation, particularly ofT cells, is thought to 
play a critical role in the pathogenesis of psoriasis. This concept is 
supported by numerous observations. First, histologic examination 
of early skin lesions has demonstrated that the epidermal hyperpla­
sia that is a key histologic feature of psoriasis is preceded by the 
infiltration ofT lymphocytes and macrophages into the skin [34]. In 
support of a key role for T cells in the pathogenesis of psoriasis, 
T -lymphocyte clones grown from psoriatic lesions have been 
reported to release growth factors that induce keratinocyte prolif­
eration [35]. The cytokine release into lesional and lesion-free 
psoriatic skin has been found to be a T-helper type 1 (Th1) 
cell-mediated response, i.e., increased expression of IL-2, IFN-y, 
and TNF-a [36]. Second, certain subtypes of psoriasis exhibit a 
strong association with particular HLA types [37]. Third, immuno­
suppressive drugs that inhibit T-cell activation and cytokine secre­
tion such as anti-CD3, corticosteroids, and cyclosporin A are 
eJfective in treating psoriasis [38]. 
The release of cytokines as the result of ongoing cellular immune 
responses is thought to contribute to the formation and persistence 
of psoriatic plaques. Localized collections of HLA-DR + keratino­
cytes are seen in psoriatic plaques [39] and likely reflect a response 
to the increased production ofIFN-')I by Th1 cells. Other cytokines 
that mediate skin inflammation and vascular endothelial adhesion 
molecule expression, such as IL-1f3, IL-6, IL-8, and TGFa, have 
also been reported to be increased in psoriatic plaques [40]. 
The mechanisms by which keratinocytes, T cells, and mono­
cytes/macrophages achieve and maintain their activated state in 
psoriatic skin lesions are poorly understood. Although this process 
is multifactorial, there are a number of reports suggesting that 
bacterial infection can trigger psoriasis [41-43]. In this regard, 50% 
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Figure 2. Proposed mechanism for local activation by superanti­
gens of restricted population(s) of T Iytnphocytes iii psoriasis. 
of patients with psoriasis harbor S. aureus on their skin [42]. 
Furthermore, in patients with guttate psoriasis, it has been reported 
that acute exacerbation is preceded by throat infection with Strep· 
tococcus pyogenes and by increases in serum antistreptococcal titers 
[43]. Patients with this form of psoriasis frequently improve with 
systemic antibiotic therapy. 
In support of these clinical observations, Cole and Wuepper [44] 
first reported that alcohol precipitates of cell-free culture filtrates 
from Streptococcus pyogenes (strain NY-5) induced increased kerati­
nocyte proliferation after intradermal injection into rabbit skin. 
These culture filtrates also had marked mitogenic activity upon 
human cultured lymphoid cells and are now known to have 
contained high levels of the streptococcal exotoxins' SPEA, SPEB, 
and SPEC. Subsequently, it was reported that psoriatic lesions could 
be induced by intradermal injection of small amounts of killed 
streptococcal material [45]. Furthermore, in vitro, both guttate and 
chronic plaque psoriasis have been shown to have enhanced 
T-lymphocyte responses to group A streptococcal antigens [46]. 
These observations suggested the hypothesis that bacterial toxins 
derived from S. atlreus and streptococci, acting as superantigens, 
could mediate the activation of epidermal HLA-DR + keratino­
cytes as well as infiltrating T cells and monocytes in at least a subset 
of patients with psoriasis. As illustrated in Figs 1 and 2, this 
selective expansion of T-cell populations locally could lead to the 
release of cytokines, which promote keratinocyte proliferation, 
endothelial cell activation, and other features of psoriasis. This 
superantigen-driven T-cell activation might be involved in both the 
induction and persistence of psoriatic lesions (Fig 3). 
With respect to the induction of psoriatic lesions, superantigen(s) 
from epicutaneous sources or from a circulating source could bind 
to MHC class II bearing APC in the dermis or epidermis (Langer-
Induction 
.J'.... _ Eplcutan80u5 
......... - Super antigen 
-. _ Circulating 
- Superantlgen 
Figure 3. Potential populations of MHC class n-positive APC in 
either the induction or persistence of psoriasis. 
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hans cell, dermal dendrocyte, dermal macrophage). If the appro­
priate V�-bearing T lymphocyte were present, APC/lymphocyte 
interaction could lead to T-cell activation by superantigen. T-cell 
proliferation, cytokine release, and the characteristic psoriatic phe­
notype would then ensue (Fig 2). On the other hand, in the 
persistence of psoriatic lesions, MHC class II-positive keratinocytes 
might also be added to the list of potential APC that could facilitate 
T-cell activation by superantigen (Fig 3). It is unlikely, however, 
that in a complex immune reaction such as psoriasis, keratinocytes 
would represent the only APC involved in T-cell activation . T 
lymphocytes recruited into an ongoing psoriatic lesion would then 
be subject to activation if a superantigen capable of binding to their 
V{3 chain were presented by appropriate MHC class II-bearing 
APe. 
As a proof of this concept, it is important to determine whe�er 
certain subtypes of psoriasis are associated with the selectIve 
expansion of T cells bearing particular V� gene segment� charac­
teristic of superantigenic stimulation. Furthermore, bactena grown 
from these patients, especially during a flare of their disease, sho�d 
secrete toxins knowu to act as superantigens. The demonstratIon 
that selective expansion of TCR V�s in the skin infiltrate reflects 
the superantigen secreted at the skin surface or in the patient's 
pharynx would offer strong evidence that the bacteria are truly 
pathogenic and the immune activation is superantigen driven: . It should be noted that a previous study of the TCR repertoIre ill 
skin lesions of patients with chronic nonpustular psoriasis did not 
demonstrate any specific selection of a single V region [47]. 
However, this may have reflected the use of a lirnited number of 
monoclonal anti-V {3s or the recruitment of bystander T cells not 
involved in the initial recognition of the inciting antigen. Because 
the acute exacerbation of guttate psoriasis has clearly been demon­
strated to be triggered by streptococcal infections, it is of consid­
erable interest to determine the potential role of streptococcal 
superantigens in the pathogenesis of this form of psoriasis. 
In a recent report, Lewis et al [48] enumerated T lymphocytes in 
peripheral blood and skin biopsy specimens from patients with 
guttate or chronic plaque psoriasis for the expression of nine TCR 
V{3 gene families, using a range of monoclonal antibodies. A 
selective expansion ofV�2+ T lymphocytes was observed in the 
skin lesions of patients from both psoriatic groups as compared with 
T lymphocytes in their peripheral blood. A less marked dermal 
increase in V�5 .1 + T cells was also observed in these patients. 
Recently, we have also analyzed skin specimens from patients with 
guttate psoriasis and found a marked increase in the percentage of 
V{32+ T cells in the skin of these individuals (Leung and Kotb, 
unpublished observations) . Furthermore, analysis of streptococcal 
isolates from the pharynx of five patients with guttate psoriasis 
revealed that all secreted SPEC, a toxin (superantigen) known to 
stimulate the selective expansion of V �2 + T lymphocytes (Leung 
and Schlievert, unpublished observations). These data strongly 
support the concept that guttate psoriasis is triggered by a superan­
tigen, most likely SPEC. 
Of interest, other V� families have also been reported to be 
elevated in the T-cell skin infiltrate of selected patients with 
psoriasis. For example, in the study by Lewis et al [48], two of the 
10 patients with guttate psoriasis showed an increase in V�12 in 
lesional skin compared with that in peripheral blood T cells . 
Conversely, in three of eight patients with chronic plaque psoriasis, 
an increase in the number of V�8+ T cells was observed. This 
latter increase was not observed in guttate psoriasis. The observa­
tion that patients with psoriasis can demonstrate divergent T-cell 
responses suggests that different antigens can trigger this disease. 
Indeed, in an earlier study by Leung et at [49] of two patients with 
plaque psoriasis triggered by infection, each demonstrated a differ­
ent pattern of V� expansion as a response to the particular 
microbial antigens expressed during their infection. Cultures from 
the psoriatic skin lesion of patient 1, who had increased V�5.1 and 
V/312 expression in her skin infiltrate, grew S. au reus secreting the 
superantigen SEB. In contrast, the skin lesion from patient 2, with 
increased expression ofV�5.1 and V�8, grew Candida albicans. SEB 
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is known to stimulate T cells in vitro to express the V �12 but not the 
V�5.1, 5.2, 6.7, or 8.1 gene segments [11J. In contrast, C. albicalls 
stimulates V�5.1 and V�8 . 1 in delayed-type hypersensitivity skin 
reactions, but not V�5.2, 6.7, or 12. Thus, the TCR V� skewing 
observed in the local infiltrate of these patients showed some 
correlation with the superantigen being secreted at their skin 
surface. The observation that the V� skewing did not correspond 
exactly with what is seen when purified superantigen is introduced 
into the skin or peripheral blood was not surprising, because T-cell 
activation in the local psoriatic lesion may be influenced by a variety 
of exogenous and endogeno�s antigens. 
Taken together, superantigen-driven T-cell activation might 
contribute to the heterogeneitY in psoriasis on two different levels. 
First, reactions to different superantigens may produce lesions with 
different V� patterns. Second, reactions to particular superantigens 
may be relatively genetically restricted. Although most MHC class 
II haplotypes are able to present superantigens, different alleles vary 
in the ability to present particular superantigens [8]. Hence, the 
development of particular types of psoriasis may be favored by 
MHC class II haplotypes associated with preferential presentation 
of particular superantigens. 
These data suggest that superantigen-driven psoriasis is one of 
many potential mechanisms of T-cell activation in psoriasis. The 
pattern of activation would be expected to be different among 
dilfen;nt patients. Further studies will be needed to determine 
whether TCR skewing is seen in the acute lesion of all forms of 
psoriasis or whether it is restricted to the subset of pso�asis 
associated with infection. Nevertheless, the current observatIons 
provide a new direction for investigating the pathogenesis of this 
fascinating skin disorder. 
CONCLUSIONS 
Cutaneous effects of bacterial toxins may be categorized into at 
least three types. The first type is the superantigen reaction, in 
which skin-infiltrating T cells bearing particular V{3 elements 
respond to the toxins presented by macrophages, Langerhans cells, 
and/or class 11+ keratinocytes . A second type is the capacity of 
toxins to affect directly the production by skin cells of cytokines 
and/ or mediators of inflammation. Among such cells, keratinocytes 
are quantitatively the major population, and keratinocytes produ�e 
cytokines with T -cell-proliferative activity in response to bactenal 
toxins. The third type of toxin-mediated intracutaneous activity 
involves nonimmune actions, e.g., the capacity of exotoxins such as 
exfoliative toxin to induce intercellular separation of granular-layer 
keratinocytes. Other examples of toxin effects that are nonsuperan­
tigenic include t4e production of vomiting and diarrhea by SEs in 
humans and primates. In these experiments, the enterotoxic effects 
of SEB could be separated from its T -cell-stimulatory properties by 
carboxymethylation of the SBB [50]. 
Because of its critical location, the skin is constantly exposed to 
a wide variety of potentially harmful environmental agents, includ­
ing bacteria. Several skin disorders are associated with the presence 
of bac�ria, in particular S. aureus and streptococci, that produce 
sllperantigenic toxins. It is likely that many of the pathologic effects 
of these toxins are due to their ability to activate T ceils, macro­
phages, Langerhans cells, and/or keratinocytes. Identification of 
the antigens or superan!:igens that trigger particular skin diseases, 
such as psoriasis or atopic dermatitis, may allow researchers to 
identify earlier events in the pathogenesis of these skin conditions 
and to develop new strategies to cope with the aberrant responses 
to these triggers. 
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